RIGL: Rigel Pharmaceuticals Inc Price to Sales
Stable revenue from hematology products funds oncology R&D and distribution for Rigel Pharmaceuticals (RIGL). The price-to-sales ratio reflects current dynamics, where 3.00 shows the actual value of the metric. The team is focused on the commercial launch of drugs and a premium benefits package. The recruitment of blood and immunity experts is based on the support of scientific research and competitive compensation.
Analytical breakdowns for Rigel Pharmaceuticals Inc (RIGL)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Capital Ratio Rigel Pharmaceuticals|RIGL - Long-Term Debt to Capital|Current Liabilities to Capital Rigel Corp|RIGL - Company Debts|Debt to Book Capitalization Ratio Rigel Pharmaceuticals Inc|RIGL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Rigel Pharmaceuticals|Critical Liquidity Ratio rigel.com
- earnings and valuation multiples information:
RIGL - Net Profit|Expected Net Income Rigel Pharmaceuticals|RIGL - P/E Multiple|Forward P/E Multiple Rigel Pharma|RIGL - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Rigel Pharmaceuticals Inc|RIGL - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Rigel Pharmaceuticals|RIGL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth rigel.com|RIGL - Earnings growth in current year|Expected earnings per share growth for next year Rigel Pharmaceuticals
- issuer revenue and sales details:
Fundamental company analysis:rigel.com RIGL
The P/S ratio compares market capitalization to sales volume, providing a real-time assessment of shifting investor sentiment regarding the value of each unit of revenue. This price-to-sales metric allows for an evaluation of whether the business is overvalued or undervalued, which is critically important for Rigel Pharmaceuticals (RIGL) during the commercial scaling of its oncology portfolio and its transition toward operational profitability.
Who Rigel Pharmaceuticals competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PTGX (Protagonist Corp)|IMVT: P/S Multiple|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols) - P/S Multiple|ADPT - Price-to-Revenue Multiple|P/S Multiple CLDX|AUPH - Price to Sales|Price-to-Revenue Ratio BioCryst BCRX|veratx.com - Price-to-Revenue Ratio|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Price-to-Sales Ratio TRML (Tourmaline)|PGEN (Precigen, Inc.) - P/S Multiple|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|P/S Multiple Upstream Bio, Inc. (UPB)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Capitalization-to-Revenue Ratio IMNM|GOSS - Price-to-Revenue Ratio|kalvista.com (KALV) - Market Cap to Revenue|SEPN: P/S Multiple|Pieris Pharma (PVLA) - P/S Multiple|SVRA (Savara Corp) - P/S Multiple|Market Cap to Revenue AnaptysBio Inc. (ANAB)|P/S Multiple ATXS|ENGN - Price to Sales|RAPT Therapeutics - Market Cap to Revenue|P/S Multiple Aerovate Therapeutics, Inc. JBIO|ACRS: Market Cap to Revenue|Kyverna Therapeutics, Inc - Market Cap to Sales Volume|TLSA: P/S Multiple|CABA - Price-to-Revenue Coefficient|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Market Cap to Revenue Theratechnologies, Inc. (THTX)|P/S Multiple AVTX|P/S Multiple Eledon Pharmaceuticals, Inc (ELDN)|Price-to-Revenue Ratio Agenus AGEN|climbbio.com - Price-to-Revenue Ratio|ZURA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient aTyr Pharma Inc ATYR|adagene.com (ADAG) - Price-to-Revenue Ratio|Ikena Oncology - Market Capitalization-to-Revenue Ratio|STTK (Shattuck Labs Inc) - P/S Multiple|Equillium Bio (EQ) - Price-to-Revenue Coefficient|P/S Multiple CNTB|immunic-therapeutics.com (IMUX) - Price-to-Revenue Multiple|Price-to-Revenue Ratio Atara Bio ATRA|InflaRx NV - Price-to-Revenue Ratio|XFOR - Price-to-Revenue Ratio|Price-to-Sales Ratio ACET|CELU: P/S Multiple|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|AKTX (akaritx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GeoVax Labs Inc - P/S Multiple|EDSA - P/S Multiple|IBIO (iBio, Inc.) - Market Cap to Revenue|Carisma Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI: Market Cap to Revenue|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Price to Sales scinai.com SCNI|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGM Bio - P/S Multiple|Price-to-Revenue Multiple iteostherapeutics.com (ITOS)|OCEA: P/S Multiple|Price to Sales TC BioPharm (Holdings) Plc (TCBP)|Price-to-Revenue Ratio Third Harmonic Bio, Inc
